BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors. 2007

Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
EntreMed Inc., 101 College Street, Toronto Medical Discovery Tower, Toronto, Ontario, Canada M5G1L7. skumar@aretetherapeutics.com

We have designed and synthesized a series of structurally novel hydroxamic acid-based histone deacetylase (HDAC) inhibitors characterized by a zinc chelating head group attached directly to a thiazole ring. The thiazole ring connects to a piperazine spacer, which is capped with a sulfonamide group. These novel molecules potently inhibit an HDAC enzyme mixture derived from HeLa cervical carcinoma cells and show potent antiproliferative activity against the breast cancer cell line MCF7.

UI MeSH Term Description Entries
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006877 Hydroxamic Acids A class of weak acids with the general formula R-CONHOH. Hydroxamic Acid,Acid, Hydroxamic,Acids, Hydroxamic
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D056572 Histone Deacetylase Inhibitors Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. HDAC Inhibitor,HDAC Inhibitors,Histone Deacetylase Inhibitor,Deacetylase Inhibitor, Histone,Deacetylase Inhibitors, Histone,Inhibitor, HDAC,Inhibitor, Histone Deacetylase,Inhibitors, HDAC,Inhibitors, Histone Deacetylase

Related Publications

Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
December 2013, Medicinal chemistry (Shariqah (United Arab Emirates)),
Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
January 2011, Bioorganic & medicinal chemistry letters,
Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.
June 2005, European journal of medicinal chemistry,
Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
January 2013, European journal of medicinal chemistry,
Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
Design, synthesis, and biological activity of hydroxamic tertiary amines as histone deacetylase inhibitors.
April 2012, ChemMedChem,
Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
October 2002, Bioorganic & medicinal chemistry letters,
Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
June 2012, Bioorganic & medicinal chemistry,
Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
August 2020, Bioorganic chemistry,
Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
September 2007, Bioorganic & medicinal chemistry letters,
Sampath-Kumar Anandan, and John S Ward, and Richard D Brokx, and Trisha Denny, and Mark R Bray, and Dinesh V Patel, and Xiao-Yi Xiao
Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
October 2009, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!